Scientific Publications

Legend Biotech sponsors research with academic institutions to evaluate our agents. The manuscripts from this research are presented below.

Year :

Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma

D Hoda, R Richards, EA.Faber, A Deol, D Porter, BD. Hunter, E Weber, H Difilippo, T Henderson-Clark, L Meaux, C Crivera, C Riccobono, A Garrett, CC. Jackson, J Fowler, P Theocharous, R Stewart, AL Lorden, A Berger

Healthcare Costs of Multiple Myeloma Patients with Four or More Prior Lines of Therapy, IncludingTriple-Class Exposure in the United States

S Jagannath, N Joseph, J He, C Crivera, AZ Fu, A Garrett, N Shah

LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, Cavo M, Vij R, Lindsey-Hill J, Dytfeld D, Angelucci E, Perrot A, Benjamin R, van de Donk NWCJ, Ocio EM, Scheid C, Gay F, Roeloffzen W, Rodriguez-Otero P, Broijl A, Potamianou A, Sakabedoyan C, Semerjian M, Keim S, Strulev V, Schecter JM, […]

Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies

AD Cohen, S Parekh, BD Santomasso, JG Pérez-Larraya, N WCJ van de Donk, B Arnulf, MV Mateos, N Lendvai, CC Jackson, KC De Braganca, JM Schecter, L Marquez, E Lee, I Cornax, E Zudaire, C Li, Y Olyslager, D Madduri, H Varsos, L Pacaud, M Akram, D Geng, A Jakubowiak, H Einsele, S Jagannath

Comprehensive BCMA Expression Profiling in Adult Normal Human Brain Suggests a Low Risk of On-target Neurotoxicity in BCMA-targeting Multiple Myeloma Therapy

M Marella, X Yao, V Carreira, MF Bustamante, HB Clark, CC Jackson, E Zudaire, JM Schecter, TD Glover, J Shenton, I Cornax